|
NAD repletion with niacin counteracts cancer cachexia.
|
Nat Commun
37012289
|
0 |
17.694 |
2023 |
|
Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia.
|
EMBO Rep
35199910
|
6 |
9.071 |
2022 |
|
Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting.
|
Antioxid Redox Signal
36310444
|
0 |
7.468 |
2022 |
|
Amino Acids in Cancer and Cachexia: An Integrated View.
|
Cancers (Basel)
36428783
|
1 |
6.575 |
2022 |
|
PGC-1α in the myofibers regulates the balance between myogenic and adipogenic progenitors affecting muscle regeneration.
|
iScience
36388980
|
1 |
6.107 |
2022 |
|
Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders.
|
Curr Osteoporos Rep
35881303
|
1 |
5.163 |
2022 |
|
Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia.
|
Sci Transl Med
34349036
|
18 |
19.319 |
2021 |
|
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).
|
Autophagy
33634751
|
509 |
13.391 |
2021 |
|
Extracellular vesicles derived from tumour cells as a trigger of energy crisis in the skeletal muscle.
|
J Cachexia Sarcopenia Muscle
34931471
|
5 |
12.063 |
2021 |
|
Mitochondrial Dysfunction in Cancer Cachexia: Impact on Muscle Health and Regeneration.
|
Cells
34831373
|
8 |
7.666 |
2021 |
|
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
|
Cells
33671024
|
8 |
7.666 |
2021 |
|
Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia.
|
Cancers (Basel)
33670497
|
11 |
6.575 |
2021 |
|
Control of Skeletal Muscle Atrophy Associated to Cancer or Corticosteroids by Ceramide Kinase.
|
Cancers (Basel)
34209043
|
5 |
6.575 |
2021 |
|
Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia.
|
Oncogenesis
33419963
|
21 |
6.524 |
2021 |
|
Sarcopenia Diagnosis: Reliability of the Ultrasound Assessment of the Tibialis Anterior Muscle as an Alternative Evaluation Tool.
|
Diagnostics (Basel)
34829505
|
10 |
0.01 |
2021 |
|
Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice.
|
J Cachexia Sarcopenia Muscle
32103619
|
25 |
12.91 |
2020 |
|
The Redox Balance: A Target for Interventions Against Muscle Wasting in Cancer Cachexia?
|
Antioxid Redox Signal
32037856
|
14 |
8.401 |
2020 |
|
Muscle NAD depletion and Serpina3n as molecular determinants of murine cancer cachexia-the effects of blocking myostatin and activins.
|
Mol Metab
32599075
|
11 |
7.422 |
2020 |
|
Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis.
|
Cancers (Basel)
30823492
|
25 |
6.126 |
2019 |
|
Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations.
|
FASEB J
30653354
|
35 |
4.966 |
2019 |
|
Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function.
|
J Mol Biol
31150737
|
32 |
4.76 |
2019 |
|
Combined Exercise Training Positively Affects Muscle Wasting in Tumor-Bearing Mice.
|
Med Sci Sports Exerc
30724848
|
22 |
4.029 |
2019 |
|
The Skeletal Muscle as an Active Player Against Cancer Cachexia.
|
Front Physiol
30833900
|
24 |
3.367 |
2019 |
|
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
|
J Cachexia Sarcopenia Muscle
29722201
|
31 |
10.754 |
2018 |
|
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia.
|
Expert Opin Investig Drugs
30526137
|
4 |
5.081 |
2018 |
|
Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.
|
Oxid Med Cell Longev
29785246
|
16 |
4.868 |
2018 |
|
Involvement of released sphingosine 1-phosphate/sphingosine 1-phosphate receptor axis in skeletal muscle atrophy.
|
Biochim Biophys Acta Mol Basis Dis
30279138
|
6 |
4.328 |
2018 |
|
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.
|
J Cachexia Sarcopenia Muscle
29130633
|
41 |
12.511 |
2017 |
|
Interference with Ca-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.
|
Front Physiol
28469577
|
9 |
3.394 |
2017 |
|
The role of vitamin D in cancer cachexia.
|
Curr Opin Support Palliat Care
28922293
|
7 |
2.073 |
2017 |
|
Vitamin D and VDR in cancer cachexia and muscle regeneration.
|
Oncotarget
28423519
|
14 |
0 |
2017 |
|
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
|
Autophagy
26799652
|
2534 |
8.593 |
2016 |
|
Autophagy is induced in the skeletal muscle of cachectic cancer patients.
|
Sci Rep
27459917
|
67 |
4.259 |
2016 |
|
Animal models for cancer cachexia.
|
Curr Opin Support Palliat Care
27454355
|
24 |
2.045 |
2016 |
|
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan.
|
Cell Metab
26094889
|
275 |
18.164 |
2015 |
|
A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.
|
J Cachexia Sarcopenia Muscle
27066318
|
29 |
9.697 |
2015 |
|
Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling.
|
J Cachexia Sarcopenia Muscle
26136415
|
19 |
9.697 |
2015 |
|
Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.
|
J Cachexia Sarcopenia Muscle
27239411
|
31 |
9.697 |
2015 |
|
Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario.
|
Semin Cell Dev Biol
26343953
|
33 |
6.614 |
2015 |
|
Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
|
Int J Cancer
26595367
|
28 |
6.513 |
2015 |
|
Role of Inflammation in Muscle Homeostasis and Myogenesis.
|
Mediators Inflamm
26508819
|
95 |
3.232 |
2015 |
|
Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations.
|
Oncotarget
26636649
|
51 |
0 |
2015 |
|
Coming back: autophagy in cachexia.
|
Curr Opin Clin Nutr Metab Care
24535215
|
30 |
4.023 |
2014 |
|
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
|
PLoS One
24427291
|
9 |
2.806 |
2014 |
|
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
|
PLoS One
25436606
|
14 |
2.806 |
2014 |
|
Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models.
|
J Lipid Res
23966665
|
12 |
4.81 |
2013 |
|
Autophagic degradation contributes to muscle wasting in cancer cachexia.
|
Am J Pathol
23395093
|
118 |
4.057 |
2013 |
|
Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients.
|
Muscle Nerve
23861230
|
10 |
2.605 |
2013 |
|
Mechanism-based therapeutic approaches to cachexia.
|
Vitam Horm
23601429
|
1 |
2.137 |
2013 |
|
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
|
Biochim Biophys Acta
23200745
|
48 |
0 |
2013 |
|
Molecular and cellular mechanisms of skeletal muscle atrophy: an update.
|
J Cachexia Sarcopenia Muscle
22673968
|
122 |
9.697 |
2012 |
|
Are there any benefits of exercise training in cancer cachexia?
|
J Cachexia Sarcopenia Muscle
22565649
|
43 |
9.697 |
2012 |
|
Caspase 2 activation and ER stress drive rapid Jurkat cell apoptosis by clofibrate.
|
PLoS One
23028936
|
3 |
2.806 |
2012 |
|
Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise.
|
J Cachexia Sarcopenia Muscle
21766055
|
39 |
9.697 |
2011 |
|
Changes in myostatin signaling in non-weight-losing cancer patients.
|
Ann Surg Oncol
21519918
|
29 |
4.041 |
2011 |
|
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
|
Int J Cancer
20039316
|
49 |
6.513 |
2010 |
|
Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia.
|
Expert Opin Biol Ther
20594117
|
17 |
3.684 |
2010 |
|
Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression.
|
Curr Med Chem
20015045
|
2 |
3.249 |
2010 |
|
Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α.
|
Amino Acids
20623149
|
14 |
3.173 |
2010 |
|
β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.
|
Int J Oncol
21184031
|
28 |
3.079 |
2010 |
|
Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition.
|
PLoS One
21048967
|
85 |
2.806 |
2010 |
|
Point mutated caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature.
|
Biochim Biophys Acta
21182936
|
10 |
0 |
2010 |
|
Are antioxidants useful for treating skeletal muscle atrophy?
|
Free Radic Biol Med
19591922
|
14 |
5.606 |
2009 |
|
Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells.
|
Biochem Pharmacol
18983831
|
3 |
4.581 |
2008 |
|
Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress.
|
Free Radic Biol Med
18053817
|
47 |
5.606 |
2007 |
|
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
|
Biochim Biophys Acta
17442496
|
3 |
0 |
2007 |
|
IGF-1 is downregulated in experimental cancer cachexia.
|
Am J Physiol Regul Integr Comp Physiol
16614058
|
66 |
2.982 |
2006 |
|
Ca(2+)-dependent proteolysis in muscle wasting.
|
Int J Biochem Cell Biol
15893952
|
59 |
3.505 |
2005 |
